RT Journal Article
T1 Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report
A1 Fuertes Recuero, Manuel
A1 Martínez De Merlo, Elena
A1 Lizasoain Sanz, Guillermo
A1 Arroba Alonso, Amanda
A1 Sánchez López, Alejandro
A1 Suárez Redondo, María
A1 Ortiz Díez, Gustavo
A1 Vázquez Fernández, Esther
AB Exocrine pancreatic carcinomas are rarely reported in dogs. A ductal pancreatic adenocarcinoma in a 10-year-old intact beagle is described in this report. The diagnosis was made based on clinical signs, imaging (abdominal ultrasound and CT scan) and histopathology. Treatment consisted of partial right lobe pancreatectomy followed by adjuvant therapy with toceranib phosphate (Palladia®) and firocoxib (Previcox®) for six months. The treatment was well tolerated, and the survival time was 445 days. To our knowledge, this is the longest survival reported in the literature for a dog diagnosed with exocrine pancreatic adenocarcinoma. The results described here may contribute to provide a better understanding about this neoplasia and potential treatment options.
PB Springer
SN 0165-7380
SN 1573-7446
YR 2024
FD 2024-03-08
LK https://hdl.handle.net/20.500.14352/102514
UL https://hdl.handle.net/20.500.14352/102514
LA eng
NO Fuertes-Recuero M*, Vazquez-Fernandez E, Lizasoain-Sanz G, Arroba-Alonso A, Sanchez-Lopez A, Martinez-de Merlo E, Suarez-Redondo M and Ortiz-Diez G. Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report. Veterinary Research Communications, 1-7. 2024. (A). ISSN: 0165-7380. Impact factor 2022: 2.200. Category: Veterinary Sciences, Quartile: 2, Position: 38 of 143. DOI: 10.1007/s11259-024-10349-5
NO Author contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by MFR, GLS, AAA, ASL, EMM, MSR, EVF and GOD. The first draft of the manuscript was written by MFR and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
NO Consejo Superior de Investigaciones Científicas
DS Docta Complutense
RD 10 sept 2024